Alnylam Pharmaceuticals Inc (ALNY)vsPrime Medicine, Inc. Common Stock (PRME)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
PRME
Prime Medicine, Inc. Common Stock
$3.52
-1.68%
HEALTHCARE · Cap: $646.38M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 80080% more annual revenue ($3.71B vs $4.63M). ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
PRME
Avoid19
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for PRME.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
No standout strengths identified
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -146.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : PRME
PRME has a balanced fundamental profile.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : PRME
The primary concerns for PRME are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while PRME is a value play — different risk/reward profiles.
PRME carries more volatility with a beta of 2.58 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 19/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Prime Medicine, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Prime Medicine, Inc. is a pioneering biotechnology firm that aims to transform healthcare with its groundbreaking Prime Editing technology, designed for accurate genetic modifications at the DNA level. The company is advancing a strong pipeline of innovative therapies targeting serious diseases, such as genetic disorders and cancer, backed by exceptional intellectual property protections. Committed to addressing critical unmet medical needs, Prime Medicine is strategically positioned to be a key player in the genetic medicine arena, showing significant potential for growth and a meaningful contribution to the evolving biopharmaceutical landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?